The US Food and Drug Administration (FDA) has approved Amgen’s supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include new data that supports the treatment of pediatric patients with Philadelphia chromosome-negative (Ph-), relapsed or refractory, B-cell, precursor acute lymphoblastic leukaemia (ALL).

The continued approval is expected to be contingent upon verification of clinical benefit in subsequent trials.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The approval is based on results from the Phase I/II '205, an open-label, multicentre, single-arm trial, which evaluated the safety of Blincyto in 93 pediatric patients.

The bispecific CD19-directed CD3 T-cell engager (BiTE) antibody construct Blincyto binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells.

"The continued approval is expected to be contingent upon verification of clinical benefit in subsequent trials."

It was granted breakthrough therapy, and orphan drug designations by the FDA, and has now been approved in the US for the treatment of Ph- relapsed or refractory, B-cell precursor ALL.

See Also:

Blincyto was granted conditional marketing authorisation in November last year in the European Union (EU) for the treatment of adults with Ph- relapsed or refractory, B-cell precursor ALL.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation.

Blincyto is administered as a continuous intravenous infusion at a constant flow rate using an infusion pump, which should be programmable, lockable and non-elastomeric, as well as have an alarm.